Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Exelixis Inc (EXEL)
Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,228,728
  • Shares Outstanding, K 325,600
  • Annual Sales, $ 1,611 M
  • Annual Income, $ 182,280 K
  • 60-Month Beta 0.68
  • Price/Sales 3.85
  • Price/Cash Flow 30.36
  • Price/Book 2.42
Trade EXEL with:

Options Overview Details

View History
  • Implied Volatility 26.82% ( +0.07%)
  • Historical Volatility 23.44%
  • IV Percentile 2%
  • IV Rank 6.40%
  • IV High 59.42% on 07/12/22
  • IV Low 24.59% on 05/15/23
  • Put/Call Vol Ratio 0.70
  • Today's Volume 316
  • Volume Avg (30-Day) 1,330
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 50,499
  • Open Int (30-Day) 57,553

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 0.15
  • Number of Estimates 8
  • High Estimate 0.23
  • Low Estimate 0.11
  • Prior Year 0.22
  • Growth Rate Est. (year over year) -31.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.08 +5.81%
on 04/28/23
20.10 -4.85%
on 05/22/23
+0.68 (+3.69%)
since 04/26/23
3-Month
16.15 +18.49%
on 03/08/23
20.56 -6.96%
on 04/06/23
+2.00 (+11.68%)
since 02/24/23
52-Week
14.87 +28.65%
on 10/11/22
22.47 -14.86%
on 07/06/22
+0.94 (+5.17%)
since 05/26/22

Most Recent Stories

More News
2 Under-the-Radar Biotech Stocks to Buy in 2023

Companies that don't make a lot of noise can still make you a lot of money.

EXEL : 19.13 (+0.53%)
SRPT : 126.82 (-1.58%)
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond

Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines.

AXSM : 69.80 (+2.51%)
EXEL : 19.13 (+0.53%)
2 Explosive Biotech Stocks to Own

The biotech industry is well-positioned to grow, thanks to breakthrough advances, rising chronic illness and government support. So, fundamentally solid biotech stocks, Genmab (GMAB) and Exelixis (EXEL)...

ARGX : 401.96 (+0.22%)
EXEL : 19.13 (+0.53%)
GMAB : 40.62 (+0.22%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 29.96 (+0.50%)
RARE : 49.83 (-0.18%)
SRPT : 126.82 (-1.58%)
PFE : 37.60 (-0.61%)
EXEL : 19.13 (+0.53%)
MRNA : 126.24 (-0.18%)
UTHR : 207.32 (-2.27%)
BIIB : 298.66 (+0.51%)
SNY : 52.51 (-0.15%)
LLY : 425.79 (-0.36%)
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip

A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals.

COMP : 3.43 (-4.19%)
$NASX : 12,975.69 (+2.19%)
PINS : 24.23 (+2.06%)
EXEL : 19.13 (+0.53%)
RDFN : 9.27 (-2.93%)
IIPR : 67.46 (+0.85%)
BIDU : 126.08 (+6.24%)
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

BMY : 63.82 (-1.15%)
EXEL : 19.13 (+0.53%)
LGND : 72.13 (+0.63%)
SPRO : 1.7700 (+1.14%)
Exelixis (EXEL) Q1 2023 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2023.

EXEL : 19.13 (+0.53%)
Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics

The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

EXEL : 19.13 (+0.53%)
Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of -30.43% and 4.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EXEL : 19.13 (+0.53%)
AFMD : 0.8277 (-5.23%)
Exelixis: Q1 Earnings Snapshot

Exelixis: Q1 Earnings Snapshot

EXEL : 19.13 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 19.63
2nd Resistance Point 19.46
1st Resistance Point 19.30
Last Price 19.13
1st Support Level 18.97
2nd Support Level 18.80
3rd Support Level 18.64

See More

52-Week High 22.47
Fibonacci 61.8% 19.57
Last Price 19.13
Fibonacci 50% 18.67
Fibonacci 38.2% 17.77
52-Week Low 14.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar